Loading...
EGFR Inhibition in Non-Small Cell Lung Cancer: Resistance, Once Again, Rears Its Ugly Head
Most patients with non-small cell lung cancer who initially respond to gefitinib or erlotinib (tyrosine kinase inhibitors) ultimately develop resistance and disease relapse. What is the mechanism for this resistance?
Na minha lista:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Public Library of Science
2005
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC549608/ https://ncbi.nlm.nih.gov/pubmed/15736989 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.0020075 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|